Navigation Links
Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies
Date:7/31/2014

SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Catylix, Inc. (Burbank, California) and Aspira Scientific (Milpitas, California) announced today the formation of a joint venture to develop and commercialize new fluorination products and related chemistry.

Developing improved biologically active molecules has benefited from the use of substituents that are chemically stable, resistant to metabolism, and combine lipophilicity with polarity to improve binding and bioavailability. Fluorinated functional groups are particularly well-suited to accomplish these objectives, often bringing improved efficacy and metabolic stability into compounds.

Catylix, Inc. and Aspira Scientific have created a joint venture to offer new fluorine-containing building blocks and reagents to customers in the pharmaceutical, agricultural, and specialty chemical industries. Dr. David Rozzell, CEO of Catylix, commented, "Through this joint venture with Aspira, Catylix will accelerate the development of its novel fluorination technologies and fluorine-substituted building blocks. Our goal is to expand our range of fluorination products and get these new compounds more quickly into the hands of chemists who need them."

Included in the product portfolio (www.aspirasci.com/fluorination) through this new joint venture will be Catylix's Trifluoromethylator® reagent for the synthesis of a wide range of CF3-containing compounds under mild reaction conditions. The broad compatibility with other functional groups allows "late-stage trifluoromethylation" during lead compound development and optimization for medicinal chemists. Dr. John Chan, CEO of Aspira stated, "The technical expertise of Catylix in fluorine chemistry together with Aspira's expertise in marketing, distribution, and production will allow rapid access of novel and unique fluorine-containing products, shortening screening and development time-lines for researchers. Aspira's access to cost-effective production facilities will ensure that these compounds will be available at economical cost structures on scale."

Dr. David Rozzell, CEO of Catylix, and Dr. John Chan, CEO of Aspira Scientific, will be available for discussions during the 2014 ACS Meeting and Exhibition in San Francisco on August 11 and 12, at Booth 1136.

About Aspira Scientific

Aspira Scientific is a science-centric enterprise dedicated to empowering scientists reach their aspirations in chemical R&D. We achieve this goal through reducing the cost of basic and applied research by offering research products with superior value in terms of price and quality. By leveraging a truly global innovation ecosystem, we also make available a broader set of next-generation enabling tools for chemical synthesis. For organizations with developmental programs, we provide custom production services via "Collaborate Locally. Commercialize Globally.™" model to afford exceptional value in terms of innovation, quality and IP assurance, and cost-efficiency. For more information on realizing your scientific aspirations now and tomorrow, please visit www.aspirasci.com.

About Catylix, Inc.

Catylix, Inc. is an early-stage company specializing in the development and commercialization of new fluorination chemistry and novel products for the incorporation of fluorine-containing functionality. For more information about Catylix, please visit http://www.catylix.com.

Logo - http://photos.prnewswire.com/prnh/20131205/AQ28432LOGO


'/>"/>
SOURCE Aspira Scientific
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Hajarian New Surgical Retractor/Aspirator May Revoultionize Surgical Retractors
2. Aspira Scientific Introduces Xeno-free rHSA Product at World Stem Cell Summit
3. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
4. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
5. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
6. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
7. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
8. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
9. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
10. Generex Augments Antigen Express Scientific Advisory Board
11. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):